Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
04/19/2012 | 07:50pm CET

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
03/16MERCK AND : First-Line Lung Cancer Data and Other New Research from Mercks Broad..
03/16MERCK AND : FDA Grants Priority Review to Merck's Supplemental Biologics License..
03/15EISAI : and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® len..
03/15Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MS..
03/15MERCK AND : Mercks sBLA for Keytruda to treat advanced cervical cancer receives ..
03/15Merck inks deal with Australian biotech firm Immutep
03/14MERCK AND : First-Line Lung Cancer Data and Other New Research from Merck’..
03/14MERCK AND : Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaborat..
03/14MERCK AND : IO Biotech inks clinical collaboration with MSD evaluating IO102 in ..
03/14MERCK AND COMPANY : Ex-dividend day for
More news
News from SeekingAlpha
10:04aBIOTECH BIO SERIES #2 : Is Gilead Still A Growth Stock? 
03/153 THINGS IN BIOTECH, MARCH 14 : Alnylam Breaks Through, Merck A Go In Cervical? .. 
03/15Cintas Is A Great Operator - Cramer's Lightning Round (3/14/18) 
03/13Merck (MRK) Presents at Cowen and Company 35th Annual Health Care Conference .. 
03/13'SAFER' DIVIDEND BIG GAIN DOW DOGS : McDonald's, Walmart, Procter, And United Pe.. 
Financials ($)
Sales 2018 41 711 M
EBIT 2018 13 778 M
Net income 2018 8 825 M
Debt 2018 13 131 M
Yield 2018 3,47%
P/E ratio 2018 16,83
P/E ratio 2019 13,83
EV / Sales 2018 3,91x
EV / Sales 2019 3,74x
Capitalization 150 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 66,5 $
Spread / Average Target 19%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Roy D. Baynes Chief Medical Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY-1.07%148 965
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
NOVARTIS-5.34%216 150
ROCHE HOLDING LTD.-10.73%201 801
AMGEN8.25%136 727